Amendment: SEC Form SC 13G/A filed by Prime Medicine Inc.
$PRME
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $1.50 | Buy → Neutral | Citigroup |
| 5/20/2025 | Overweight → Neutral | Analyst | |
| 5/20/2025 | Buy → Neutral | H.C. Wainwright | |
| 12/10/2024 | $10.00 | Mkt Outperform | JMP Securities |
| 5/20/2024 | $10.00 | Buy | H.C. Wainwright |
| 5/16/2024 | $10.00 | Neutral → Buy | Citigroup |
| 4/22/2024 | $17.00 | Buy | Chardan Capital Markets |
| 4/8/2024 | Buy | TD Cowen |
Citigroup downgraded Prime Medicine from Buy to Neutral and set a new price target of $1.50
Analyst downgraded Prime Medicine from Overweight to Neutral
H.C. Wainwright downgraded Prime Medicine from Buy to Neutral
CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in the following upcoming conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 5, 2025, at 10:30 a.m. ET in New York, NY.Goldman Sachs 46th Annual Global Healthcare Conference: Fireside chat on Monday, June 9, 2025, at 2:40 p.m. ET in Miami Beach, FL. Live audio webcasts of each presentation will be available under "Events & Presentations" in the News & Events section of the Company's website at www.pr
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff Marrazzo, member of the Board of Directors, named Executive Chair -- -- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points -- CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotech
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels believed to be potentially curative -- -- Rapid engraftment observed in both neutrophils and platelets -- -- Encouraging safety profile; no serious adverse events related to PM359 -- -- Initiating efforts to explore continued clinical development opportunities for PM359 external to Prime Medicine -- CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new cl
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
DEFA14A - Prime Medicine, Inc. (0001894562) (Filer)
8-K - Prime Medicine, Inc. (0001894562) (Filer)
-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile -- -- Received U.S. FDA Rare Pediatric Drug designation for PM359 for CGD; initiated IND-enabling studies and remain on track to file IND application in 2024 -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's third patent, No. 11,795,452 --
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio's shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson's Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 -- -- Allan Reine, M.D., CFO, to succeed Keith Gottesdiener, M.D., as CEO; Jeff Marrazzo, member of the Board of Directors, named Executive Chair -- -- Implementing cost cutting measures to significantly reduce cash needs in advance of key data inflection points -- CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotech
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Allan Reine, M.D., as the Company's Chief Financial Officer, effective January 17, 2024. A seasoned financial executive with over twenty years' experience in the biotechnology industry, Dr. Reine will be responsible for the company's financing strategy and investor relations, and will oversee all financial operations as Prime Medicine begins its transition into a clinical company. "I am delighted to welcome Allan to Prime Medicine. He brings tremendou
-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE platform to multiplex edit CAR-T cells to be presented at ASGCT Annual Meeting -- -- Expanded Board of Directors with appointment of Jeff Marrazzo, former CEO of Spark Therapeutics -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's second patent, No. 11,643,652, and allowed third patent application, No. 17/751,599 -- -- Cash, cash equivalents, investments and restricted cash balance of $263.0 million as of March 31, 2023 -- CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME)
SC 13D/A - Prime Medicine, Inc. (0001894562) (Subject)
SC 13G/A - Prime Medicine, Inc. (0001894562) (Subject)
SC 13G - Prime Medicine, Inc. (0001894562) (Subject)